Hi Cherie,

Got my numbers crossed.....the Affirm trial showed a 42% Reduction in the Risk of Disability Progression and Sustained 67% Reduction in Relapse Rate. That would mean that 58% of patients could have disability progression and 33% have relapses.

For some docs to say that it is extremely uncommon for MS patients to have disease progression or replapes while on Tysabri is really stretching it, don't you think! Just reading comments on other MS Forums from some patients on the drug seems to negate that kind of statement.

Take care.

Harry